Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients

Giulia Morsica, Giampaolo Bianchi, Sabrina Bagaglio, Camilla Conte, Stefania Salpietro, Lucy Porrino, Caterina Uberti-Foppa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.

Original languageEnglish
Pages (from-to)317-321
Number of pages5
JournalNew Microbiologica
Volume34
Issue number3
Publication statusPublished - Jul 2011

Fingerprint

Ritonavir
HIV
Safety
Liver
Transaminases
Darunavir
Enzymes

Keywords

  • Darunavir
  • HCV
  • HIV
  • Liver toxicity
  • Ritonavir

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients. / Morsica, Giulia; Bianchi, Giampaolo; Bagaglio, Sabrina; Conte, Camilla; Salpietro, Stefania; Porrino, Lucy; Uberti-Foppa, Caterina.

In: New Microbiologica, Vol. 34, No. 3, 07.2011, p. 317-321.

Research output: Contribution to journalArticle

@article{61ed467aaea44660b80ea618d5186d45,
title = "Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients",
abstract = "The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.",
keywords = "Darunavir, HCV, HIV, Liver toxicity, Ritonavir",
author = "Giulia Morsica and Giampaolo Bianchi and Sabrina Bagaglio and Camilla Conte and Stefania Salpietro and Lucy Porrino and Caterina Uberti-Foppa",
year = "2011",
month = "7",
language = "English",
volume = "34",
pages = "317--321",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "3",

}

TY - JOUR

T1 - Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients

AU - Morsica, Giulia

AU - Bianchi, Giampaolo

AU - Bagaglio, Sabrina

AU - Conte, Camilla

AU - Salpietro, Stefania

AU - Porrino, Lucy

AU - Uberti-Foppa, Caterina

PY - 2011/7

Y1 - 2011/7

N2 - The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.

AB - The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.

KW - Darunavir

KW - HCV

KW - HIV

KW - Liver toxicity

KW - Ritonavir

UR - http://www.scopus.com/inward/record.url?scp=84860415854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860415854&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 317

EP - 321

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 3

ER -